Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · IEX Real-Time Price · USD
19.37
-0.85 (-4.20%)
At close: Jul 19, 2024, 4:00 PM
19.38
+0.01 (0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $681.75M in the twelve months ending March 31, 2024, with 1.88% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $167.12M with 4.23% year-over-year growth. In the year 2023, Pacira BioSciences had annual revenue of $674.98M with 1.22% growth.
Revenue (ttm)
$681.75M
Revenue Growth
+1.88%
P/S Ratio
1.32
Revenue / Employee
$957,520
Employees
712
Market Cap
901.60M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
Dec 31, 2008 | 13.93M | 5.58M | 66.95% |
Dec 31, 2007 | 8.34M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
HealthStream | 282.88M |
Harrow Health | 138.68M |
Cronos Group | 93.03M |
AbCellera Biologics | 35.79M |
AnaptysBio | 22.96M |
Liquidia | 15.97M |
Viridian Therapeutics | 288.00K |
Perspective Therapeutics | -304.00K |
PCRX News
- 11 days ago - Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 - GlobeNewsWire
- 13 days ago - Top 5 Health Care Stocks That May Explode In July - Benzinga
- 18 days ago - This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
- 7 weeks ago - Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 - GlobeNewsWire
- 2 months ago - Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes - GlobeNewsWire
- 2 months ago - Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program - GlobeNewsWire
- 2 months ago - Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire